New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
06:45 EDTSQNM, DGXSequenom upgraded to Outperform from Market Perform at William Blair
William Blair upgraded Sequenom (SQNM) to Outperform after its survey indicated a high likelihood of non-invasive prenatal testing moving quickly into the $1B-plus average-risk pregnancy market. The firm also believes Sequenom's agreement last week with Quest Diagnostics (DGX) provides added market coverage.
News For SQNM;DGX From The Last 14 Days
Check below for free stories on SQNM;DGX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
18:35 EDTSQNMOn The Fly: After Hours Movers
Subscribe for More Information
16:33 EDTSQNMSequenom reports Q2 adjusted EPS (7c), consensus (11c)
Subscribe for More Information
16:32 EDTSQNMSequenom enters license agreement with Mayo Medical Laboratories
Subscribe for More Information
July 25, 2014
08:32 EDTDGXQuest Diagnostics price target raised to $74 from $68 at Maxim
Subscribe for More Information
July 24, 2014
07:05 EDTDGXQuest Diagnostics narrows 2014 adjusted EPS view to $4.00-$4.10 from $3.95-$4.15
Subscribe for More Information
07:02 EDTDGXQuest Diagnostics reports Q2 adjusted EPS $1.08, consensus $1.06
Subscribe for More Information
July 22, 2014
07:08 EDTDGXLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.
July 21, 2014
11:21 EDTSQNMSequenom VisibiliT launch unlikely to have near-term impact, says Ladenburg
Subscribe for More Information
07:02 EDTSQNMSequenom subsidiary launched VisibiliT test in international markets
Sequenom announced that its wholly owned subsidiary, Sequenom Laboratories, will soon launch the VisibiliT laboratory-developed test in international markets. The VisibiliT test utilizes maternal age, fetal fraction and the relative amount of chromosomal material for chromosomes 21 and 18 to generate a highly accurate, personalized risk score.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use